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VEGFA: Just one of multiple mechanisms for Sex-Specific 
Vascular Development within the testis?
Kevin M. Sargent, Renee M. McFee, Renata Spuri Gomes, and Andrea S. Cupp
Department of Animal Science, University of Nebraska-Lincoln, 3940 Fair Street, Lincoln, 
Nebraska 68583-0908, USA
Abstract
Testis development from an indifferent gonad is a critical step in embryogenesis. A hallmark of 
testis differentiation is sex-specific vascularization which occurs as endothelial cells migrate from 
the adjacent mesonephros into the testis to surround Sertoli-germ cell aggregates and induce 
seminiferous cord formation. Many in vitro experiments have demonstrated that Vascular 
Endothelial Growth Factor A (VEGFA) is a critical regulator of this process. Both inhibitors to 
VEGFA signal transduction and excess VEGFA isoforms in testis organ cultures impaired 
vascular development and seminiferous cord formation. However, in vivo models using mice 
which selectively eliminated all VEGFA isoforms: in Sertoli and germ cells (pDmrt1-
Cre;Vegfa−/−); Sertoli and Leydig cells (Amhr2-Cre;Vegfa−/−) or Sertoli cells (Amh-Cre;Vegfa−/− 
and Sry-Cre;Vegfa−/−) displayed testes with observably normal cords and vasculature at postnatal 
day 0 and onwards. Embryonic testis development may be delayed in these mice; however, the 
postnatal data indicate that VEGFA isoforms secreted from Sertoli, Leydig or germ cells are not 
required for testis morphogenesis within the mouse. A Vegfa signal transduction array was 
employed on postnatal testes from Sry-Cre;Vegfa−/− versus controls. Ptgs1 (Cox1) was the only 
upregulated gene (5-fold). COX1 stimulates angiogenesis and upregulates, VEGFA, Prostaglandin 
E2 (PGE2) and PGD2. Thus, other gene pathways may compensate for VEGFA loss, similar to 
multiple independent mechanisms to maintain SOX9 expression. Multiple independent 
mechanism that induce vascular development in the testis may contribute to and safeguard the sex-
specific vasculature development responsible for inducing seminiferous cord formation, thus, 
ensuring appropriate testis morphogenesis in the male.
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Introduction
Many scientists have been investigating the factor or factors that are responsible for 
inducing endothelial cell migration from the adjacent mesonephros into the developing 
indifferent gonad for years. Endothelial cell migration and vascular development has been 
demonstrated as one of the first steps for directing seminiferous cord formation and 
initiating the testis differentiation pathway (Albrecht et al. 2000; Tilmann and Capel 1999). 
Within this review we will discuss the reasoning behind investigating VEGFA, its ever 
evolving complexity due to transcriptional and posttranslational regulation, and how it acts 
on cells through multiple receptors and co-receptors as indicated mainly by rodent models 
(Dehghanian et al. 2014; Qiu et al. 2009; Vieira et al. 2010). Since infertility in the human 
male has been on the rise for almost 50 years (Carlsen et al. 1992, 1995; Carlsen et al. 1993; 
Juul et al. 2014), more information into gonadal development and how fertility is affected 
when mutations arise is critical to developing therapies for male related infertility issues. In 
the last decade, there have also been interesting data to suggest that male infertility may be 
associated with other health risks since men with subnormal sperm counts also had reduced 
lifespans when evaluated between 1949 and 1985. This correlation between infertility and 
shorter lifespans in men may be due to lifestyle and behavior choices, conditions in utero or 
their genetic composition (Groos et al. 2006). There have been numerous incidences 
reported in the scientific literature of prenatal exposure to compounds which alter gene 
expression through epigenetic mechanisms and may affect reproduction and a host of other 
critical functions (e.g. immune). Thus, prenatal or in utero conditions may be one avenue 
that can be altered to increase reproductive function in men and also improve their lifelong 
health status. Since an altered uterine environment may influence gene expression that is 
necessary for testis development, any additional information on how testes develop may also 
increase our ability to develop measures to diagnose male infertility disorders that arise 
through prenatal programming or epigenetic causes.
How does a testis develop from an indifferent gonad?
The Sertoli cell expresses Sry (sex determining region of the Y chromosome, a gene that is 
on the short arm of the Y chromosome) and is the first cell to differentiate in the testis 
(Magre and Jost 1991). In the mouse, Sry is only briefly expressed (E10.5 to 12.5) and its 
primary function is the upregulation of Sox9 (SRY-box 9) (Harley et al. 2003). Much of the 
fate of the developing testis appears to be reliant on appropriate Sertoli cell differentiation 
and on the ability of Sox9 expression to be maintained at high levels (Figure 1) thereby 
leading to transcription of many genes to initiate testis development (Harley et al. 2003). 
Furthermore, expression of Sox9 upregulates other genes such as Fibroblast Growth Factor 9 
(Fgf9) which, in addition to cementing the testis differentiation pathway, may antagonize 
genes such as Wingless type MMTV integration site family, member 4 (Wnt4), that if 
overexpressed or not antagonized will enable development of the female pathway (Jameson 
et al. 2012; Shan et al. 2009) (Figure 1).
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What is the origin of the Sertoli cell …a cell that is thought to direct testis 
development?
The precursors of the Sertoli cells are the early somatic progenitor cells which develop from 
the coelomic epithelium. The coelomic epithelium is derived from the mesonephros and as it 
differentiates it thickens, a phenomenon proposed to be due to gene expression of Sry. Many 
different transcription factors are critical for the proper development of the gonadal 
primordium which is enveloped by the coelomic epithelium such as EMX2 (empty spiracles 
homeobox 2), WT1, NR5A1 (nuclear receptor subfamily 5, group A, member 1, formerly 
SF1), LHX9 (LIM homeobox protein 9), GATA4 (GATA binding protein 4), ZFPM2/FOG2 
(zinc finger protein, multitype 2) and others (Munger and Capel 2012; Wilhelm et al. 2007). 
Both the thickening of the gonadal primordium to form the coelomic epithelium and the 
expression of Sry is critical to allow Sertoli cells to develop. At least 20% of the Sertoli cells 
need to express Sry in order for a testis to arise from the indifferent gonad (Burgoyne et al. 
1995; Patek et al. 1991) (Figure 1). Furthermore, Sox9 has to be upregulated by E11.2 
through the actions of Sry for testis development to continue; if Sox9 is not upregulated then 
proliferation of the Sertoli cells will arrest along with testis development (Figure 1). In other 
species such as domestic livestock, Sry is maintained much longer and appears to have other 
functions (Daneau et al. 1996; Parma et al. 1999; Payen et al. 1996; Pelliniemi and Lauteala 
1981).
Sox9
Originally Sox9 is expressed in the indifferent gonad by the pre-Sertoli/granulosa cells and is 
transcribed at a very low copy number by SF1. When Sry is expressed, Sox9 is upregulated 
in the testis and its expression is silenced in the ovary (Kobayashi et al. 2005). Because Sry 
expression is short-lived, it is critical that other factors continue to upregulate and maintain 
Sox9 expression (Figure 1). Sox9 induces the expression of Ffg9 and prostaglandin D2 
synthase (Ptgds), in which the latter generates PGD2 (Wilhelm et al. 2007). One function of 
both of these genes is to maintain upregulated Sox9 expression (Rossitto et al. 2015). 
Furthermore, Sox9 also upregulates itself through two mechanisms. It binds its own 
enhancer in a feed-forward fashion (Sekido and Lovell-Badge 2008) and by maintaining 
upregulation of a transcription factor ER71/ETV2 (ets variant 2) which is initially increased 
through Sry expression (DiTacchio et al. 2012).
FGF9
Elimination of FGF9 or its receptor FGFR2 (fibroblast growth factor receptor 2) can cause 
male-to-female sex reversal given that FGF9 down regulates or suppresses the Wnt pathway 
which would otherwise promote female gonadal development (Bagheri-Fam et al. 2008; 
Colvin et al. 2001; Jameson et al. 2012; Jeays-Ward et al. 2003; Siggers et al. 2014; Vainio 
et al. 1999) (Figure 1). Wnt4 knockout mice are sex-reversed similarly to knockouts of 
FGF9 (Shan et al. 2009). It was determined that FGF9 antagonizes the actions of WNT4 and 
thus prevents the ovarian pathway and allows for seminiferous cords to develop (Jameson et 
al. 2012; Kim et al. 2006). FGF9 also is critical for Sertoli cell proliferation necessary to 
provide enough Sertoli cells to differentiate to form clusters with germ cells.
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PGD2
The gene encoding Ptgds (Lipocalin-type prostaglandin D2 synthase), an enzyme that 
produces PGD2, was identified in 2002 to be initially expressed in the developing urogenital 
ridges and later in Sertoli cells and prospermatogonia at around E11.5 (Adams and McLaren 
2002) (Figure 1). Expression of the Ptgds gene in the developing testis was noted to be in a 
similar pattern as both Sry and Sox9 starting at the center and moving to the anterior poles in 
the developing testis (Wilhelm et al. 2007). Furthermore, expression of L-PGDS protein was 
present in E12.5 male gonads in both Sertoli and germ cells (Moniot et al. 2009) that it is 
regulated upstream through either COX1 (cyclooxygenase 1) or COX2 pathways (Rossitto 
et al. 2015). However, neither male Cox2- nor Cox1- knockout mice are infertile; thus, there 
may be multiple ways to promote production of L-PGDS in order to have a sufficient 
quantity of PGD2 (Gerena et al. 2000a; Gerena et al. 2000b). PTGDS is up-regulated by 
Sox9 but not Sry (Wilhelm et al. 2007). PGD2 acts through its receptor, DP1 (prostaglandin 
D2 receptor 1) in Sertoli cells, to translocate the cytoplasmic SOX9 protein, to the nucleus to 
influence gene expression.
How is PGD2 regulated?
Many endocrine disruptors such as phthalates, bisphenol and NSAIDS that inhibit COX 
activities also reduce PGD2 production as demonstrated in a mouse Sertoli cell line and fetal 
testis cultures (Kristensen et al. 2011a; Kristensen et al. 2012; Kristensen et al. 2011b). 
Thus, it appears that the COX signaling pathway is involved and potentially downstream of 
SOX9 to induce expression of PGD2. In addition to PGD2, COX1 and 2 can stimulate 
upregulation of other prostaglandins such as PGE2 which is proangiogenic and can further 
enhance the expression of VEGFA (Cheng et al. 1998; Pai et al. 2001). Furthermore, there 
appears to be a positive feedback pathway between COX2 and VEGFA with each of them 
increasing the other's expression as well as VEGFA upregulating upstream factors in the 
arachidonic pathway to further enhance COX2 activity. COX1 is thought to be constitutively 
expressed while most of the effects of hypoxia and VEGFA may be through stimulation of 
the inducible COX2 (Iniguez et al. 2003) (Fig. 2). Since, angiogenic inhibitors do not appear 
to inhibit COX1; it is possible that the constitutively-expressed COX1 may safeguard some 
function of angiogenesis within the developing testes.
Mesonephric cell migration directs testis development: are the migrating 
mesonephric cells peritubular myoid cells or endothelial cells?
As Sertoli cells differentiate and establish intimate contact with germ cells, they form 
clusters with germ cells aptly named Sertoli-germ cell clusters (Tesarik et al. 2002). Germ 
cells are of extragonadal origin and migrate to the indifferent gonad prior to Sertoli cell 
differentiation (Mintz and Russell 1957; Ozdzenski 1969). Germ cells do not appear to 
induce seminiferous cord formation since cord formation still occurs in the testis of c-Kit 
(kit oncogene, also known as c-Kit) knockout despite a lack of primordial germ cells 
migration to and colonization of the indifferent gonad (Nocka et al. 1989; Runyan et al. 
2006).
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Very elegant studies have demonstrated that mesonephric cells migrating from the 
mesonephros are necessary for cord formation and later that the developing testis from an 
indifferent gonad directs mesonephric cell migration (Buehr et al. 1993). This migration can 
even pass through an ovary inserted between the mesonephros and the developing testis 
(Tilmann and Capel 1999). Initially the migrating cells were thought to be pre-peritubular 
myoid cells since that cell type is what forms around seminiferous cords and aids later in 
development of the blood-testis barrier (Buehr et al. 1993). However, others have 
demonstrated that all cells that migrated are endothelial cells (Combes et al. 2009; Cool et 
al. 2008).
Since the Sertoli cells are the first cell to differentiate in the testis (Magre and Jost 1991), 
they were thought to be the catalyst for induction of endothelial cell migration via secretion 
of factors that serve as chemoattractants for mesonephric cells. Later it was determined that 
mesonephric cell migration not only directs seminiferous cord formation but also may 
induce proliferation of the somatic cells up to a certain threshold to restrict their number. 
Early studies identified factors that had receptors within PTM cells such as neurotrophins 
(NT) (Levine et al. 2000) and PDGF's (Puglianiello et al. 2004). The low affinity receptor 
for the neurotrophins, NGFR (nerve growth factor receptor), is expressed in cells which 
appear to migrate from the mesonephros into the differentiating testis and by P0 it is only 
expressed in a thin layer of cells which appear to have differentiated into the PTM layer that 
surrounds each seminiferous cord (Russo et al. 1999). Other experiments demonstrated that 
NT3 may be involved in mesonephric cell migration and Trk knockout mice contained fewer 
cords within the testis than wild type mice, in addition to some fused or odd shaped cords 
(Cupp et al. 2002; Cupp et al. 2003).
The focus then became the endothelial cells because most of the cells that migrate from the 
mesonephros contained endothelial cell markers. In addition, sex-specific vasculature 
develops in the testis and ovary with large differences noted in vascular reorganization and 
origin in the testis compared to the ovary (Bott et al. 2010; Combes et al. 2009; Cool et al. 
2008). It was postulated Sertoli cells produced angiogenic or vascular-specific factors to 
induce endothelial cell migration and cause sex-specific vascular development and 
seminiferous cord formation (Bott et al. 2010; Tilmann and Capel 1999). Again the question 
was what angiogenic or vascular-specific factors were produced by the Sertoli cells around 
the time of sex-specific vasculature development and seminiferous cord formation?
What composes the VEGFA ligand receptor family and how does VEGFA signal through its 
receptors and co-receptors?
The VEGF family was a logical growth factor family to evaluate its involvement in 
endothelial cell migration within the developing testis due to its ability to stimulate 
endothelial cell migration, survival, proliferation and differentiation to initiate 
vasculogenesis and angiogenesis within developing organs and tumors (Ferrara et al. 2003; 
Lee et al. 2015). The VEGF family is composed of VEGFA, VEGFB, VEGFC, VEGFD, 
and PGF (Placental Growth Factor, previously known as PlGF). VEGFA is the most studied 
family member and is critical for angiogenic processes (Ferrara et al. 2003). Even the 
disruption of one allele (heterozygotic deletion) causes embryonic lethality between E11 and 
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E12. Since neovascularization does not occur in these mice, this suggests that the embryonic 
lethality is due to a lack of oxygen and nutrients delivery to organs and that VEGFA is 
critical for most organ functions (Ferrara et al. 1996).
What are the receptors to which VEGFA binds?
VEGFA binds to two different tyrosine kinase receptors: kinase insert domain protein 
receptor (KDR also known as VEGFR2 and FLK1), and FMS-like tyrosine kinase 1 (FLT1, 
also known as VEGFR1) (Ferrara et al. 2003). Both the KDR and the FLT1 receptors 
contain an extracellular domain comprised of seven immunoglobulin-like (Ig-like) folds (Fig 
3). The function of the Ig-like folds were determined through mutation experiments 
indicating the VEGFA high affinity ligand binding domain is within the 2nd and 3rd folds 
while the 1st and 4th Ig-like fold regulate the ability for the ligand to bind and the receptor to 
dimerize (Davis-Smyth et al. 1998; Fuh et al. 1998; Shinkai et al. 1998; Vieira et al. 2010). 
The KDR receptor is the primary receptor that VEGFA signals through (Cunningham et al. 
1999; Kroll and Waltenberger 1997; Seetharam et al. 1995; Waltenberger et al. 1994; 
Wheeler-Jones et al. 1997). This is mainly due to the observation that the tyrosine 
phosphorylation sites on the FLT1 receptor (in the regulatory juxtamembrane domain and 
five within the C-terminus; Figure 3) are never phosphorylated when the VEGFA ligand 
binds endothelial cells.
FLT-1 receptor—why is it called the decoy receptor?
FLT1 has higher affinity for VEGFA than KDR (Gille et al. 2001; Olofsson et al. 1998; 
Waltenberger et al. 1994). Since there was no phosphorylation of its tyrosine residues the 
main function of this receptor was thought to be to function as a decoy receptor for VEGFA 
and, thus, to inhibit VEGFA-KDR ligand-receptor interactions and subsequent signal 
transduction. Presumably this was to allow for inhibition of vascularization of tissues 
(Ferrara 2000; Zachary and Gliki 2001). This is supported by a study demonstrating that 
FLT1/VEGFR1 knockout mice that die at E8 and E9 is due to a failure of endothelial cells to 
assemble into a vasculature circuit (Fong et al. 1995). Since most KDR-mediated VEGFA 
binding results in vascularization of tissues, an increase in FLT1 production to inhibit 
binding to KDR may be a method to regulate vascularization. Recent reports have also 
suggested that FLT1 may prevent endothelial cell apoptosis and thus is a potential survival 
factor (Vieira et al. 2010). This may be due to FLT1 but not KDR being regulated by 
hypoxia. Within the promoter region of the FLT1 receptor is a binding site for hypoxia 
inducible factor 1, alpha subunit (HIF1A) (Gerber et al. 1997). Thus, FLT1 expression along 
with upregulation of VEGFA through hypoxia (since there is a HIF1A promoter site in the 
VEGFA promoter, as well) may allow for survival of these cells and stimulation of some 
sort of vascular growth to provide oxygen to the tissue. Due to alternative splicing, FLT1 is 
not only present in a membrane-bound form but also has a soluble form (sFLT1) that acts 
similarly to binding proteins. Thus this soluble form may also act as a decoy receptor to 
sequester VEGFA away from KDR (Kearney et al. 2004). An increase in sFLT1 has been 
demonstrated to occur in pathological states such as preeclampsia (Autiero et al. 2003; 
Hiratsuka et al. 2001). Thus, regulation of the soluble as well as membrane forms of FLT1 
are critical to allow for appropriate vascularization of tissues.
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FLT1 signaling pathways
FLT1 contains several potential tyrosine autophosphorylation sites in the c-terminus and 
also juxtamembrane transmembrane domain. These sites are suppressed by a repressor 
element located in the juxtamembrane domain which inhibits the phosphorylation of these 
tyrosine residues after VEGFA binding (Gille et al. 2000). However in monocytes and 
macrophages this repression is not present and there is no information to suggest how this 
occurs other than secretion of factors that relieve this inhibition. Thus, in these particular 
cell types, FLT1 can recruit several different accessory proteins such as protein kinases 
related to SRC (Rous sarcoma oncogene), FYN (fyn proto-oncogene) and YES1 
(Yamaguchi sarcoma viral (v-yes) oncogene homolog 1) (Chou et al. 2002).
Does FLT-1 signal in the somatic cells of the testis or is it repressed similarly to 
endothelial cells?
Caires et al. (2012) demonstrated that there was increased phosphorylation of tyrosine (Y) 
1333 within the FLT1 receptor in somatic cells at postnatal day 3 (P3) in mice compared to 
activation in gonocytes, Sertoli, and Leydig cells at P1 (Caires et al. 2012). Also inhibitors 
which blocked both FLT1 and KDR simultaneously were effective in testis organ cultures in 
inhibiting both sex-specific vascular development as well as seminiferous cord formation 
(Bott et al. 2006) (Table 1). To our knowledge, no experiments have been conducted to 
determine if FLT1 signals in the somatic or germ cells of the testis early in development, but 
it is possible that this occurs. Since FLT1 is not present until after seminiferous cord 
formation in the testis (Bott et al. 2006) it may not be critical. However, since FLT1 can be 
upregulated by hypoxia, it may be a failsafe mechanism to initiate neovascularization in 
some tissues outside the testis where VEGFA or KDR are limiting and vascularization of the 
tissue is critical for survival.
Why is KDR thought to be the primary receptor through which VEGFA signals?
In contrast to FLT1, the KDR receptor is autophosphorylated on several tyrosine residues 
after ligand binding and receptor dimerization, that have been depicted in the human in the 
kinase insert domain Figure 3): Y951 (Y949 mouse); in the tyrosine kinase domain: Y1054 
and Y1059 (Y1053, Y1057 mouse); and in the C-terminal domain Y1175 and Y1214 
(Y1173,Y1212 mouse) (Eliceiri et al. 1999; Vieira et al. 2010; Werdich and Penn 2005). 
Most phosphorylation experiments have been conducted in endothelial cells; however, these 
tyrosine residues recruit different downstream signaling molecules when phosphorylated to 
induce different events (Eliceiri et al. 1999; Vieira et al. 2010; Werdich and Penn 2005). 
This autophosphorylation is actually a form of trans-phosphorylation that is prevented until 
the conformation of KDR changes following VEGFA binding and the receptor monomers 
come into close juxtaposition (Tao et al. 2001).
KDR phosphotyrosines such as Y951 and Y1175 are recognized by SRC family kinases 
which have been shown to modulate endothelial proliferation and migration (Eliceiri et al. 
1999; Vieira et al. 2010; Werdich and Penn 2005). Many different knockout mouse models 
have been developed which mutate or eliminate these tyrosine residues in order to determine 
their function (Figure 3). The Y951 phosphotyrosine works through TSAd (T Cell–Specific 
Adapter) and Src and is involved in endothelial cell permeability and migration while both 
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Y1175 and Y1214 also are involved in endothelial cell proliferation or migration as 
indicated through mutation experiments (Rajagopal et al. 1999). The tyrosine residue Y1214 
works through growth factor receptor bound protein 2 (GRB2) and has been implicated to be 
in control of actin reorganization and cell migration which is thought to occur through 
CDC42 (cell division cycle 42) and MAPK (mitogen-activated protein kinase) cascades 
(Lamalice et al. 2004) (Figure 3). Many different signal transduction pathways occur 
through Y1175: activation of phospholipase C (PLC) gamma, protein kinase C (PKC), and 
MAPK to cause proliferation. Src is recruited to this residue as well as SHB (src homology 2 
domain-containing transforming protein B) which will allow for migration, survival and 
permeability of endothelial cells (Aouadi et al. 2006). SHB controls endothelial cell 
migration through focal adhesion kinase (FAK) in a PI3 (phosphoinositide-3) kinase-
mediated pathway (Kriz et al. 2006) (Figure 3). Caires et al., 2012 demonstrated that during 
early postnatal periods, the 1054 phosphotyrosine is autophosphorylated (1053 in the 
mouse), and VEGFA signaling through KDR is clearly present in both Sertoli, Leydig and 
germ cells at different stages of early postnatal development (Caires et al. 2012). Thus, these 
pathways should be explored to determine which phosphotyrosines are specifically 
necessary for VEGFA's function within the developing testis during sex-specific 
vascularization.
KDR is critical to embryogenesis since KDR knockout mice die at E8.5 to E9.5 (Shalaby et 
al. 1995). These embryos lack blood island formation in the yolk sac and experience a 
dramatic reduction in haematopoetic precursors, suggesting KDR is necessary for 
vasculogenesis. Furthermore, since they mark the early haemangioblast that differentiates 
into endothelial cells as well as haematopoeitic progenitors, it is possible that KDR is also 
involved in haematopoiesis as well as vascularization of tissues through endothelial cells 
(Ciau-Uitz et al. 2013; Jaffredo et al. 2005; Medvinsky et al. 2011; Murray 1932). 
Interestingly, mice carrying only a single amino acid mutation that prevents KDR activation 
of ERK 1/2 die in utero due to vascular defects suggesting that phosphorylation of this 
receptor is critical to multiple vasculature functions within the developing embryo (Sakurai 
et al. 2005).
What is the expression pattern of the KDR, FLT-1 receptors during testis 
development?
Expression of KDR occurs relatively early and marks sex-specific vascular development in 
both the testis and ovary as indicated in KDR-LacZ transgenic mice (Bott et al. 2010). 
Expression of KDR is apparent on cells which appear to be migrating into the testis at the 
time of sex-specific migration. Later as seminiferous cords form and are apparent, these 
KDR-LacZ marked cells are present around the seminiferous cords (Bott et al. 2010; Bott et 
al. 2006). Since the KDR receptor signals through tyrosine kinase autophosphorylation, 
several different tyrosine kinase inhibitors were utilized to determine how this may affect 
seminiferous cord formation and sex-specific vascular development in testis organ cultures. 
In rat testis organ cultures, VEGFRTKI (a tyrosine kinase inhibitor specific to KDR and 
FLT1) inhibited sex-specific vascular development (reduction by 90% in all vascular 
development in the testis; Table 1) and seminiferous cord formation (Bott et al. 2006). In 
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addition, a KDR specific inhibitor, SU1498, reduced vascular development by 90% and 
perturbed cord formation (Bott et al. 2006) (Table 1). Furthermore, KDR-LacZ-positive 
staining in mouse testis organ cultures was reduced at day 1, 2 and 3 of culture by 66%, 90% 
and 99%, respectively, when they were treated with VEGFR-TKI. These data suggest that 
endothelial cell migration, proliferation and survival may have been blocked which 
prevented the testis from being vascularized (Bott et al. 2010). Thus, it does appear that 
KDR-LacZ marked cells migrate into the testis and can be inhibited by a specific VEGFR 
inhibitor. Other inhibitors to PI3 kinase have also been demonstrated to detriment sex-
specific vascular development but only reduce vascular development by 56% (Bott et al. 
2006) despite perturbing seminiferous cord formation (Bott et al. 2006; Uzumcu et al. 
2002b) (Table 1). Inhibition of the MAPK pathway also alters cord formation (Uzumcu et 
al. 2002b), but vascular development was not evaluated. Since VEGFA signals through 
KDR to stimulate both MAPK and PI3 kinase, these data support of a role for VEGFA in 
regulating sex-specific vascular development within the developing rodent testis.
FLT1, however, is not expressed in the rodent until after cord formation in the male (Bott et 
al. 2006) while both KDR and FLT1 are expressed early in the ovary (McFee et al. 2009). 
KDR, FLT1 and VEGFA are expressed by oocyte cysts, oocytes and pregranulosa/granulosa 
cells of all stage follicles at P0, P3, and P10 as well as in theca cells of late antral follicles 
(McFee et al. 2009). There is a possibility that FLT1 expression in the ovary sequesters the 
VEGFA ligand and prevents it from binding to KDR and to block endothelial cell migration 
within the ovary at the time sex-specific vascular development occurs in the testis.
What are the alternatively spliced products of VEGFA and what are their 
function(s)?
Of the 25,000 genes in the human genome, at least 70% are alternatively spliced, and 
abnormal alternative splicing can be correlated with a large number of human genetic 
deficiencies (Black 2003; Matlin et al. 2005). VEGFA is transcribed from a single gene that 
is alternatively spliced into many different isoforms depending on the cell type of interest. 
Many VEGFA isoforms have been identified (VEGFA111, 121, 165, 148, 145, 183, 189, 
206), and the most common VEGFA isoforms that have been studied are human angiogenic 
VEGFA206, VEGFA189, VEGFA165, VEGFA145 and VEGFA121 (Figure 4). The 
numbers on the isoforms denote the number of amino acids and in the rodent there is one 
less amino acid for each isoform: VEGFA205, VEGFA188, VEGFA164, VEGFA144, 
VEGFA120 (Fig. 4). For this review we will utilize the rodent VEGFA isoforms since much 
of the research discussed will be in the rodent (Giacca 2010; Hoeben et al. 2004; Kajdaniuk 
et al. 2011).
Within the Vegfa gene, there are 8 exons and all VEGFA isoforms contain exons 1–5 except 
for a newly identified isoform, VEGFA111, which contains only 1–4 and exon 8. A signal 
peptide is located within exons 1 and 2 and upon cleavage, produces a mature peptide. In 
exon 5, there are cleavage sites for plasmin and matrix metalloproteinases. Since 
VEGFA111 does not contain exon 5, this isoform is resistant to their cleavage and is a 
critical compound utilized in therapies for different cell ischemia (Houck et al. 1991; 
Mineur et al. 2007). Exons 6a and 7 encode heparin binding domains and isoforms 
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containing these exons bind to cell surfaces and are not as diffusible as isoforms that do not 
contain these exons. Also contained within exons 6a and 7 are a neuropilin binding site 
(Keyt et al. 1996; Lee et al. 2005). The 5' untranslated region (UTR) of Vegfa is 
approximately 1038 nucleotides in humans and consists of 3 CUG start codons, an AUG 
initiation codon and two internal ribosome entry sites (IRESes) which can control VEGFA 
translation. The 3'UTR consists of polyadenylation signals and AU-rich response element 
which allows for response to stabilizing and destabilizing mRNAs (Konopatskaya et al. 
2006; Seifi et al. 2012) (Figure 4).
The VEGFA205 isoform contains all exons and is proposed to bind more tightly to 
extracellular matrix proteins in addition to being greater in amino acid number than other 
isoforms. The VEGFA188 isoform has 2 heparin binding domains, remains relatively close 
to the cell in which it was secreted, and acts locally to support branching of vasculature. The 
VEGFA164 isoform contains only one heparin binding domain and has intermediate 
diffusibility, and has a prominent role in the formation of large blood vessels. The 
VEGFA120 isoforms lacks a heparin binding domain, is the most diffusible, and can migrate 
the farthest from the secreted cells. The differences in diffusibility of these different VEGFA 
isoforms allow for the development of a chemoattractant gradient which induces endothelial 
cells to migrate toward cells which produce VEGFA (Carmeliet and Collen 1999; Ferrara 
2010; Grunstein et al. 2000; Krilleke et al. 2009; Simons 2007; Veikkola and Alitalo 1999).
What is the expression and potential actions of VEGFA isoforms in the 
developing testis?
The presence of multiple VEGFA isoforms differing in number of amino acids was 
identified in the developing rat testis: VEGFA120, 164 and 188 (Bott et al. 2006) (Figure 4). 
Using a pan antibody to all VEGFA isoforms it was demonstrated that protein for the pan-
VEGFA (which detects both angiogenic and antiangiogenic isoforms) was lower at E13 and 
increased by P4. Sertoli cells had the greatest abundance of panVEGFA expression around 
the time of cord formation (Bott et al. 2006).
It does not appear that a chemoattractant gradient for VEGFA exists in the ovary around the 
time of seminiferous cord formation in the rat testis because the only VEGFA isoforms that 
are present are VEGFA164 and VEGFA120. The two higher molecular weight VEGFA 
isoforms VEGFA188 and VEGFA205 have not been detected (McFee et al. 2009); thus, we 
hypothesize that there is no viable chemoattractant gradient to allow for endothelial cell 
migration from the mesonephros into the ovary.
Furthermore, treatment of E13 rat testis organ cultures with VEGFA120 and VEGFA164 
causes formation of altered (absent, swollen and misshaped) seminiferous cords as well as 
dramatically increased vascular density (160 and 157% that of controls; Table 2). Thus, 
excess VEGFA angiogenic isoforms 164 and 120 can elicit detrimental effects on testis 
development and potentially have as dramatic effects as inhibition of VEGFA signal 
transduction discussed earlier (Bott et al. 2006) (Table 1). All of these VEGFA angiogenic 
isoforms have been shown to bind both KDR and NRP1, but even though there may be 
binding of VEGFA120 (which does not have a heparin and thus NRP1 binding domain) to 
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NRP-1, the bridging to KDR does not appear to occur. This may affect the amplification of 
the VEGFA120 signal transduction as well as the recycling of the KDR receptor within the 
cell (Pan et al. 2007).
VEGFA antiangiogenic isoforms
In 2002, a second set of sister isoforms was identified through alternative splicing and 
replacement of exon 8a with 8b (Bates et al. 2002) (Figure 4). These sister VEGFA isoforms 
were considered inhibitory to angiogenic functions and were labeled antiangiogenic VEGFA 
isoforms. Several antiangiogenic isoforms have been identified- VEGFA212b, 
VEGFA145b, 183b, 189b, 165b, and 121b (Bates et al. 2002; Dehghanian et al. 2014; 
Woolard et al. 2004) (Fig. 3). VEGF165b is normally expressed in tissues but is down-
regulated in prostate and renal tumors suggesting a role in inhibiting the vasculogenic and 
angiogenic actions of other VEGF isoforms (Bates et al. 2002; Woolard et al. 2004). Several 
reports have suggested that these antiangiogenic VEGFA isoforms may function to 
antagonize angiogenic VEGFA isoform functions through binding of the receptors and 
preventing angiogenic isoforms from binding (Qiu et al. 2009).
Much controversy has ensued over whether these “b” isoforms exist or whether they are 
artifacts of alternative splicing (Harris et al. 2012). While it is true that determining the 
difference in the angiogenic vs the antiangiogenic isoforms has been a challenge, data from 
our laboratory and others using either recombinant angiogenic or antiangiogenic VEGFA 
isoforms has resulted in very different outcomes that demonstrate the existence of divergent 
VEGFA isoforms (Artac et al. 2009; Baltes-Breitwisch et al. 2010; Bates et al. 2013; Caires 
et al. 2012; McFee et al. 2009).
For instance, the VEGFAxxxb antibody (detects all antiangiogenic isoforms but sold as 
antiVEGFA165b) detected antiangiogenic isoforms in germ cells from E14 to E16 with 
expression in the interstitium by P0 (Baltes-Breitwisch et al. 2010). This result in expression 
was very different from the panVEGFA antibody which detects all VEGFA isoforms where 
expression was detected in Sertoli cells and potentially some germ and Leydig cells (Bott et 
al. 2006). When we used this antibody to the exon 8b (which will neutralize antiangiogenic 
isoforms and allow endogenous VEGFA angiogenic isoforms to bind) on E13 rat testis 
organ cultures we had similar results as treating with recombinant VEGFA120 or 
VEGFA164 (Table 2). Either dose of VEGFAxxxb antibody, dramatically increased 
vascular density (195%) versus control testes compared to increases in vascular density of 
160% (VEGFA164) or 157% (VEGFA120) (Table 2). In addition, the seminiferous cords 
were swollen, perturbed, or misshapen which was very similar to what was seen with the 
recombinant angiogenic VEGFA isoforms treatment (Baltes-Breitwisch et al. 2010). Thus, it 
appears that removal of the antiangiogenic isoforms increases the amount of endogenous 
angiogenic VEGFA isoforms that can bind to the VEGFA receptors and elicit similar effects 
to treatments with recombinant angiogenic VEGFA isoforms. Thus, from our data and 
others we would suggest that the antiangiogenic isoforms do exist whether they are 
produced from alternative splicing or through other recently identified means.
Whole testis western blots conducted with the antiangiogenic VEGFAxxxb antibody did not 
demonstrate major differences in the levels of antiangiogenic VEGFA isoform abundance 
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during early testis development, but the immunohistochemistry clearly indicated that 
VEGFAxxxb isoforms were not expressed in somatic cells and only in germ cells during 
early testis development (Baltes-Breitwisch et al. 2010). Quantitiative PCR demonstrated a 
5-fold greater abundance of antiangiogenic VEGFA165b in the ovary vs the testis at E13 
which indicated that antiangiogenic isoforms may be inhibiting angiogenic VEGFA isoform 
functions related to endothelial cell migration or development of chemoattractant gradients.
Recently, a paper was published in Cell (Eswarappa et al. 2014) which identified yet another 
antiangiogenic VEGFA isoform in human and bovine endothelial cell lines that is produced 
by programmed translational readthrough which has a cis-acting element in the Vegfa 3'UTR 
that serves a dual function (Figure 4). It can encode the shortened peptide but can also direct 
the programmed readthrough by decoding the UGA stop codon (Figure 4). A heterogeneous 
nuclear ribonucleoprotein (hnRNP) A2/B1 binds this element and promotes readthrough, 
producing a product that has exon 8a and 8b. This product acts similarly to antiangiogenic 
isoforms and is down regulated in certain cancers (Eswarappa et al. 2014). The authors of 
this paper have named this isoform VEGFAx. The Ax is named for the Ax element which is 
a 62 nucleotide extension inserted between the 2 stop codons which normally would confer 
either angiogenic (with exon 8a) or antiangiogenic isoforms (with exon 8b; Figure 4). Thus, 
the binding protein hnRNP A2/B1 binds the A2/B1 response element (A2RE) in the Ax 
element and positively regulates VEGFA readthrough. This finding is exciting since this is 
the first time that a trans factor has been identified that regulates translational readthrough. 
Furthermore, most translational readthrough was only thought to occur in evolutionarily 
lower-ordered species such as Drosophila, viruses, etc. Since the VEGFAx protein acts like 
an antiangiogenic isoform, more experiments are needed to determine if this protein is 
present only in certain cell types that produce this trans-factor hnRNP A2/B1 or whether 
they are ubiquitous (Eswarappa et al. 2014).
In experiments where VEGFA isoforms have been subcloned from primary bovine 
granulosa cells, some VEGFA isoform PCR subcloned products contained both exon 8a and 
8b suggesting that there is a readthrough product in the bovine (McFee, Spuri Gomes, Artac, 
Summers, Pohlmeier, Brauer, Kurz, Cushman, Wood and Cupp, unpublished observations) 
(Figure 4). This was not the case for subcloned VEGFA from rat granulosa or Sertoli cells. 
In addition, there were subcloned products which only contained either the 8a or 8b in the 
bovine and rat without the Ax product. Thus, within each cell, the necessary machinery- 
whether it is splicing proteins or proteins that allow for programmed read through- may be 
present at critical physiological states to ensure the appropriate balance of VEGFA 
angiogenic and antiangiogenic isoforms. More experiments are needed to ensure the 
VEGFAx product exists; however, if these data are confirmed there could be an 
evolutionary change in insertion of the Ax sequence (62 nucleotides) which may provide 
different functions in higher evolved mammals.
Are there differences in VEGFA angiogenic and antiangiogenic isoform 
actions on their receptors?
Neuropilin 1 (NRP1) was originally identified as a receptor in the nervous system and was 
found to modulate semaphorin signals (He and Tessier-Lavigne 1997; Takahashi et al. 1998) 
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and direct neuronal axon guidance. However, NRP1 has also been found to be critical for 
vascular development in cooperation with the VEGFA angiogenic isoforms in many 
different angiogenic processes (Kawasaki et al. 1999). NRP1 knockout mice die between 
10.5 and 12.5 and have vasculature development defects as well as heart and neural defects 
suggesting that NRP1 is critical for both vascular and neuronal development (Kawasaki et 
al. 1999). NRP1 can bind to semaphorins instead of VEGFA and this impairs endothelial 
cell migration (Miao et al. 1999). Semaphorins are present within the testis and appear to be 
secreted by Sertoli cells (Perala et al. 2005). Whether semaphorins are antagonistic to 
vascular development within the testis this is yet unknown. Alternatively, NRP/VEGFA 
complexes binding to FLT1 can also prevent endothelial cell migration and vascular 
development (Miao et al. 1999) so there are potentially many check points that are present 
within the testis to prevent over-vascularization to ensure development of the seminiferous 
cords.
NRP1 is a co-receptor to VEGFA but it does not bind either KDR or FLT-1 but instead 
binds to a region on the VEGFA ligand (Figure 4). Because KDR lacks a PDZ-binding 
domain it cannot interact with a PDZ protein synectin (which is also called GIPC1 or NIP). 
NRP1 has a SEA motif which allows for PDZ protein synectin binding. KDR can utilize 
NRP1 bound to VEGFA angiogenic isoforms as a bridge to enhance signal transduction and 
also allow for appropriate trafficking of NRP1 within the cell to allow for receptor recycling 
(Cai and Reed 1999; Wang et al. 2006).
Due to the presence of exon 8b rather than 8a, the VEGFA antiangiogenic isoforms cannot 
bind NRP1 since much of their binding region is within the exon 8a region. Thus, 
elimination of NRP1 or overexpression will only affect angiogenic VEGFA isoform 
functions (Kawamura et al. 2008). When NRP1 is bound to VEGFA164 and then they bind 
and signal through KDR, this causes the KDR receptor to be recycled through Rab5, Rab4 
and Rab11 vesicles. However, antiangiogenic VEGFA cannot bind NRP1. Therefore, when 
VEGFA164b binds to KDR, KDR bypasses the Rab11 vesicles in cells and is routed to the 
Rab7 vessicles which moves KDR to the degradation pathway. Also, if the SEA binding 
motif for synectin is deleted from NRP1, will attenuate the receptor-ligand signal 
amplification since the SEA carboxyterminal domain of NRP1 mediates the events to allow 
for KDR recycling via Rab11 positive endosomes (Ballmer-Hofer et al. 2011).
How are NRP1 receptors expressed and regulated within the gonad?
NRP1 receptors are present early in both the testis and ovary (Walker, Lu, Clopton, and 
Cupp, unpublished observations) and have the potential to interact with VEGFA and present 
both to KDR and FLT1. Because FLT1 is present during gonadal development, it is possible 
that FLT1 is sequestering NRP1 and VEGFA away from KDR and limiting signal 
transduction and subsequent endothelial cell migration in the ovary (Baltes-Breitwisch et al. 
2010). An inhibitor to the NRP1 co-receptor, Je-11, was utilized to determine its effects on 
E13 rat testis organ cultures. Initially this inhibitor was thought to be specific only to KDR 
but later was found to inhibit only NRP1. This inhibitor caused a 42% reduction in vascular 
development with a less defined coelomic vessel and cords that were either not present or 
perturbed (Bott et al. 2006) (Table 1). This inhibitor was not as effective as the inhibitors 
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either to KDR alone or to KDR and FLT1 simultaneously, suggesting that KDR can signal 
and cause vascular development independent of NRP1 which has been demonstrated in 
many different endothelial cells and systems with vascularization (Vieira et al. 2010). 
However these results do demonstrate its role in enhancement of KDR signaling. Through 
altered receptor recycling we can envision a function for NRP1 in development of 
endothelial cell migration, arteriogenesis–mainly the coelomic vessel-, and induction of cord 
formation within the developing testis.
What happens in vivo when VEGFA isoforms are eliminated in somatic and 
germ cells during testis development?
In order to determine if VEGFA was critical for testis development multiple conditional 
knockout mouse lines were developed to eliminate all VEGFA isoforms in: Sertoli and some 
germ cells (pDmrt1-Cre;Vegfa−/−); Sertoli and Leydig cells (Amhr2-Cre;Vegfa−/−); and 
Sertoli cells only (Amh-Cre;Vegfa−/− and Sry-Cre;Vegfa−/−). To date, testes formed 
normally in these male mice by P0 and there do not appear to be differences in vasculature 
based on published work from our laboratory (Lu et al. 2013) as well as on unpublished 
results (Sargent, Spuri Gomes, Essink, Kurz, Pohlmeier, Ferrara, Bouma, McLean, and 
Cupp; Sargent, Essink, Bremer, Pohlmeier, and Cupp, unpublished observations) in VEGFA 
or NRP1 knockout versus the control testes. Instead of effects on vasculature, our laboratory 
has demonstrated effects on male fertility through altered spermatogonial stem cell 
maintenance (Lu et al. 2013). Furthermore, using different VEGFA angiogenic and 
antiangiogenic isoforms we also have demonstrated different effects on number of 
spermatogonial stem cells in endogenously depleted recipients (Caires et al. 2012). It is 
possible that vascular development in these males is delayed embryonically; however, what 
we can state is that VEGFA does not appear to be required for testis development since 
these testes contain a coelomic vessel and seminiferous cords that form into seminiferous 
tubules. Furthermore, from the P0 time period the only phenotype that appears to be 
abnormal is the number of germ cells at different stages and the number of undifferentiated 
spermatogonia leading to differences in number of sperm (Lu et al. 2013). These findings 
were echoed by measurement of VEGFA in roe deer where expression correlated more with 
transition of germ cell stages than with testis microvasculature (Wagener et al. 2010). When 
Vegfa was in control of and overexpressed by the MMTV promoter in mice, the animals 
were infertile. This infertility was thought to result, in part, from testicular spermatogenic 
cell arrest which further demonstrates non-endothelial effects of VEGFA in the testis 
(Korpelainen et al. 1998).
Due to our conditional knockout mouse data it does not appear that VEGFA is absolutely 
required for normal testis development. In many ways this makes sense because throughout 
testis development there are multiple factors that upregulate expression of genes to ensure 
proper differentiation of a testis. NR5A1 induces initial expression of Sox9 which is then 
upregulated by SRY and SOX9 (Sekido and Lovell-Badge 2008) and SOX9 not only 
upregulates FGF9 and PTGS but it also upregulates itself (DiTacchio et al. 2012). A role of 
both PTGS and FGF9 is to continually provide sustained expression of SOX9 (Rossitto et al. 
2015) (Fig. 1). Thus, since sex-specific vascular development drives seminiferous cord 
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formation it would logically follow that there are multiple mechanism which allow for this 
to happen– potentially in the absence of one such as VEGFA.
What are some potential alternative pathways to initiate endothelial cell 
migration and sex-specific vascularization that do not utilize VEGFA?
Cox1/2 pathway
VEGFA is regulated through increased HIF1A (hypoxia inducible factor 1, alpha subunit) 
upregulation during hypoxia. It is possible that the COX pathway through PGE2 upregulates 
VEGFA as well as direct upregulation through COX2 (Fig. 2). Postnatal day 30 whole testes 
were collected from Sry-Cre;Vegfa−/− conditional knockout mice and compared to controls 
for differences in genes within the VEGFA signal transduction pathway using a VEGFA 
signal transduction array plate. When the data analyzed with Ingenuity Pathway Analysis 
(IPA), the COX1 (PTGS1) constitutively expressed gene was upregulated 5-fold (Sargent, 
Spuri Gomes, Essink, Kurz, Pohlmeier, Ferrara, Bouma, McLean, and Cupp; Sargent, 
Essink, Bremer, Pohlmeier, and Cupp, unpublished observations). These data indicate that 
elimination of VEGFA (in this case in Sertoli cells) may allow for compensatory 
mechanisms which regulate other angiogenic factors to allow for normal tissue 
development.
Other VEGF ligands
VEGFB knockout mice are fertile and viable with no apparent phenotype; however, they do 
exhibit a subtle cardiac phenotype (Aase et al. 1999). Transcription of the Vegfb gene is not 
stimulated by hypoxia or other growth factors, cytokines, etc. VEGFB binds to FLT1 and 
NRP1, while VEGFC binds to VEGFR3 and KDR and enhances vasculature within the 
lymphatic system. VEGFC is expressed in the heart, placenta, ovary, small intestine and 
thyroid gland (Olofsson et al. 1999). In the embryo, it is expressed in regions where 
lymphatic vessels sprout from embryonic veins. Similar to VEGFB this gene is not regulated 
by hypoxia but interleukin 1 (IL1) and tumor necrosis factor (TNF) can increase VEGFC 
(Kukk et al. 1996). VEGFD is expressed in the lung, heart, skeletal muscle, colon and small 
intestine. In embryos, VEGFD is most abundant in the lung. Like VEGFC, it binds to both 
VEGFR3 and KDR (Olofsson et al. 1999). There have been no reports of VEGFB or 
VEGFC present in or involved with testis development, but due to their potential actions 
through VEGF receptors, these could be two potential candidates that may function in 
VEGFA's absence to initiate sex-specific vascular development.
What about other growth factors that have similar functions to VEGFA that 
could compensate for sex-specific vascular development?
Platelet Derived Growth Factor
Platelet derived growth factor receptor alpha (PDGFRα) and PDGFRβ are receptors for 
PDGF-AA, PDGF-BB, PDGF-CC and PDGF-DD and these receptors are structurally 
similar to the VEGFR's (Heldin 2013). PDGFB is expressed in endothelial cells and Pdgfb 
and Pdgfrb knockout mice are embryonic lethal during late gestation due to widespread 
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hemorrhaging and capillary dilation (Hellstrom et al. 1999; Leveen et al. 1994; Lindahl et 
al. 1997; Soriano 1994). Fetuses appear normal, but the absence of vascular smooth muscle 
cells and /or pericytes leads to cardiovascular complications. In the rat, PDGF-AA, PDGF-
BB and their receptors are expressed in human fetuses (Basciani et al. 2002), and PDGF-
BB, when inhibited, has been demonstrated to affect vascular development and perturb or 
totally inhibit seminiferous cord formation in the mouse (Puglianiello et al. 2004). Inhibitors 
to the PDGF-BB signal transduction pathway (PGFR-specific inhibitor Tyrophostin) have 
also inhibited seminiferous cord formation in the rat (Uzumcu et al. 2002a). Furthermore, 
PDGF has also been identified to work cooperatively with VEGFA in vascular events and 
remodeling within the testis (Cool et al. 2011) during the process of sex-specific vascular 
development. Thus, PDGF and its receptors may comprise a mechanism where endothelial 
migration and seminiferous cord formation occur in the absence of VEGFA isoforms.
R-spondin homolog
Recently, RSPO1 (R-spondin homolog), which is necessary for ovarian development, has 
been shown to induce angiogenesis within the developing testis and to inhibit actions of the 
dickkopf homolog 1 (Dkk1) gene which perturbs endothelial branching by inhibiting 
PDGFB (Caruso et al. 2015). Interestingly, RSPO1 can rescue DKK1 inhibition of 
angiogenesis indicating that perhaps RSPO1 is critical for necessary availability of PDGFB 
for endothelial cell branching during testis development. These actions of RSPO1 are 
thought to be mediated through beta catenin (CTNNB1) since testes treated in vitro with 
RSPO1 exhibit enhanced nuclear translocation of CTNNB1 which will affect gene 
expression within the nucleus (Caruso et al. 2015).
VEGF Receptors that bind other ligands
It is possible that the receptors that VEGFA signals through may elicit effects following 
binding by other ligands within the VEGF family to induce endothelial cell migration. An 
example of this is the potential for FLT1 to be induced through hypoxia and cooperate with 
PGF (Placental Growth Factor to promote pathological angiogenesis that occurs during 
diseases and disorder such as pre-eclampsia (Autiero et al. 2003; Hiratsuka et al. 2001). 
FLT1 upregulation can be stimulated by hypoxia (Gerber et al. 1997) and has been shown to 
activate PGF in VEGF-responsive monocytes which release proangiogenic factors. Further, 
FLT1 tyrosine kinase signaling mediates chemotactive macrophage migration in response to 
PGF and both VEGF, and PGF promotes macrophage survival during tumor angiogenesis 
(Adini et al. 2002; Barleon et al. 1996; Clauss et al. 1996; Hiratsuka et al. 1998; Selvaraj et 
al. 2003). Recently macrophage migration was demonstrated to occur during testis 
development and the authors implicated that VEGFA was expressed by macrophages and 
that vascular development may, thus, be directed by these macrophages (DeFalco et al. 
2014). These are intriguing data and may suggest that macrophages derived from the yolk 
sac (which are extraembryonic along with primordial germ cells) are critical for sex-specific 
vascular development. So the possibility of macrophages directing endothelial cell migration 
is a potential mechanism that should be further evaluated.
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Summary
While there is overwhelming in vitro evidence to support the theory that VEGFA and its 
receptors, FLT1, KDR, and NRP1, are critical for sex-specific vascular development which 
can allow for seminiferous cord formation, conditional knockout data in mice where 
VEGFA was eliminated in Sertoli, Leydig and germ cells do not support this theory. 
Because the development of the testis is so critical to the propagation of the species, 
suggesting that VEGFA can only be the critical regulator of this process may be somewhat 
simplistic. Just as SOX9 has multiple regulators which sustain its expression, there are 
potentially many independent angiogenic pathways which contribute to the migration of 
endothelial cells to initiate seminiferous cord formation. In this review article, we have 
suggested several other pathways which may independently mimic the actions of VEGFA in 
supporting endothelial cell migration and development of this quite extraordinary vascular 
development within the testis. We, along with others, investigating this area will have many 
more years to work on unraveling the complexities of this pathway, to gain a better 
understanding of how the testis develops, and paving new avenues for treating infertility 
which may be a predictor of male health and lifespan.
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Figure 1. 
Gene expression during testis morphogenesis. Depicted above the timeline is a network 
pieced together based on gene and protein interactions in the literature related to sex-specific 
vascular development and sexual differentiation. The bottom of the figure depicts different 
stages of testis development. PGC = primordial germ cell, SRY = sex determining region of 
Chr Y, SXO9 = SRY (sex determining region Y)-box 9, WNT4 = wingless-type MMTV 
integration site family, member 4, PGD2 = prostaglandin D2, PDGFR = platelet derived 
growth factor receptor, FGF9 = fibroblast growth factor 9, COX = cyclooxygenase 1/2, 
VEGFA = vascular endothelial growth factor A.
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Figure 2. 
Proposed pathway of prostaglandin synthesis and interaction with the cyclooxygenase 
pathways and VEGFA. PLA2 = phospholipase A2, PG = prostaglandin, COX= 
cyclooxygenase, VEGFA = vascular endothelial growth factor A.
Sargent et al. Page 27
J Endocrinol. Author manuscript; available in PMC 2016 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. 
VEGF receptors which are critical to the actions of VEGFA. Pictured is binding of 
angiogenic VEGFA isoforms to either KDR (top right) or FLT1 (top left). Only angiogenic 
isoforms of VEGFA bind to NRP1 (top). Antiangiogenic VEGFA isoform binding to either 
KDR (bottom left) or FLT1 (bottom right) results in less and different signal transduction 
than angiogenic. Antiangiogenic VEGFA isoforms are unable to bind NRP1 (bottom). 
Phosphorylation sties are depicted as “P” within a circle. Y = tyrosine, VEGFA = vascular 
endothelial growth factor A, KDR = kinase insert domain protein receptor, FLT1 = fms-like 
tyrosine kinase 1, NRP1 = neuropilin 1, TSAd = T-cell Specific Adaptor, SRC = Rous 
sarcoma oncogene, PI3K = phosphatidylinositol 3-kinase, GRB2 = growth factor receptor 
bound protein 2, CDC42 = cell division cycle 42, (p38)MAPK = mitogen-activated protein 
kinase, HSP27 = heat shock protein 27, PLCγ = phospholipase C gamma, PKC = protein 
kinase C, SHC/SCK = src homology 2 domain-containing transforming protein, SHB = src 
homology 2 domain-containing transforming protein B, AKT = thymoma viral proto-
oncogene, eNOS = nitric oxide synthase 3, endothelial cell, FAK = focal adhesion kinase.
Sargent et al. Page 28
J Endocrinol. Author manuscript; available in PMC 2016 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 4. 
VEGFA gene containing all exons and both heparin- and NRP1-binding sites as well as the 
canonical stop codons targeted for alternative splicing between either angiogenic or 
antiangiogenic isoforms (A). Various rodent angiogenic VEGFA isoforms (B, left) and 
antiangiogenic isoforms (B, right) have been identified following alternative splicing. In the 
human and bovine, the amino acids numbers differ from rodent. Pictured are the most well 
known/studied angiogenic VEGFA isoforms (left, C) and antiangiogenic isoforms (top right, 
C). Also depicted is the recently identified VEGFAx that possesses antiangiogenic 
properties in humans and bovines (bottom right, C).
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Table 1
Signal Transduction Inhibitors of VEGFA Signaling and their effects on Rat Embryonic Testis Cord 
Formation and Vascular Development in vitro (Data from Bott et al. 2010)
Signal Transduction Pathway Inhibitor Effect on Cord 
Formation
Effects on Vasculature PECAM1 Staining
Inhibits KDR SU1498 (Calbiochem, #572888) No cord formation Little vasculature, no 
coelomic vessel
10%
Inhibits KDR and FLT1 VEGF-TKI (Calbiochem, #676475) No cord formation No vasculature dividing, 
no coelomic vessel
10%
Inhibits NRP1 Je11 (Calbiochem, #676494) No cords/
perturbed cord 
formation
Coelomic vessel, some 
microvessels, but 
reduced density
58%
Inhibits PI3K LY294002 (Calbiochem, #440202) Cords perturbed or 
swollen
Weak coelomic vessel, 
less dense vasculature
54%
VEGFA = vascular endothelial growth factor A
KDR = kinase insert domain protein receptor
FLT1 = FMS-like tyrosine kinase 1
NRP1 = neuropilin 1
PI3K = phosphatidylinositol 3-kinase
PECAM1 = platelet/endothelial cell adhesion molecule 1
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Table 2
Effects of Recombinant VEGFA Protein or VEGFAxxxb Antibody on Rat Embrynic Testis Testis Cord 
Formation and Vascular Development in vitro (Data from Baltes-Breitwisch et al. 2010)
Recombinant VEGFA Protein Effect on Cord Formation Effects on Vasculature PECAM Staining
VEGFA120 Swollen cords with some perturbed 
(R&D Systems, #494-VE)
Thickened coelomic vessel, more 
vasculature between cords
157%
VEGFA164 Some cords misshapen or perturbed 
(R&D Systems, #564-RV)
Thickened coelomic vessel, more 
vasculature between cords that formed
160%
VEGFAxxxb antibody (5 ng/ml) Swollen or perturbed cords, 
misshapen cords (Abcam, #ab14994)
Increased vasculature all throughout testis 195%
VEGFAxxxb antibody (50 ng/ml) Swollen or perturbed cords, 
misshapen cords (Abcam, #ab14994)
Increased vasculature all throughout testis 195%
VEGFA = vascular endothelial growth factor A
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